Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder

•Zuranolone is a novel, investigational treatment under development for MDD•Zuranolone showed greater benefit vs placebo and active comparators•Results showed a favorable NNT and NNH for zuranolone vs all comparators•MDD patients may benefit from an improved benefit-to-risk profile with zuranolone Z...

Full description

Bibliographic Details

Published in:	Journal of affective disorders 2021-04, Vol.285, p.112-119
Main Authors:	Arnaud, Alix, Suthoff, Ellison, Stenson, Katie, Werneburg, Brian, Hodgkins, Paul, Bonthapally, Vijayveer, Jonas, Jeffrey, Meyer, Kellie, O'Day, Ken
Format:	Article
Language:	English
Subjects:	Antidepressive Agents - therapeutic use Clinical Trials, Phase II as Topic Depressive Disorder, Major - drug therapy efficacy Humans major depressive disorder number needed to harm number needed to treat Pregnanes - therapeutic use Pregnanolone Psychiatric/Mental Health Pyrazoles - therapeutic use tolerability zuranolone
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!